ReviewMeta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with antidepressant efficacy
Graphical abstract
Introduction
Nowadays depression has still an enormous economic burden due to both direct and indirect costs, in the order of tens of billions of dollars each year in the US alone (Halfin, 2007, Wang et al., 2003). Several factors are responsible of this economic burden. Among the most relevant ones, there are the still unsatisfactory rates of response and remission (Machado et al., 2006, Papakostas et al., 2006) (47 and 33%, respectively, in the STAR*D cohort) (Trivedi et al., 2006). Furthermore, initial side effects and failure to perceive benefit are common reasons of early discontinuation (Masand, 2003). The detection of factors that could predict response and minimize side effects of treatments therefore remains an essential goal. Clinical factors have been extensively investigated, but results are still controversial and cannot be translated into the clinical practice (Papakostas et al., 2008, Serretti et al., 2009). On the other hand, several lines of evidence suggested that genetic factors contribute for about 50% of the antidepressant response (Angst, 1965, Franchini et al., 1998, Kirchheiner et al., 2004, Maier and Zobel, 2008, Serretti et al., 1998), although so far the inconsistency of results has not allowed clinical applications.
Despite this discouraging scenario, some polymorphisms were repeatedly associated to antidepressant response, particularly a polymorphism within the promoter of the serotonin transporter gene (SLC6A4), i.e. the 5-HTTLPR. It is a 44 bp insertion/deletion involving two units in a sequence of sixteen repeated elements and possibly influences serotonin transporter (SERT) expression, with the long (l) allele associated with a twice basal expression compared to the short (s) allele (Heils et al., 1996). 5-HTTLPR is a priori excellent candidate for genetic studies, since SERT is one of the main targets for antidepressant drugs and the primary target for SSRIs. Furthermore, it has been associated with several psychiatric disorders with affective symptomatology (i.e. bipolar disorder, anxiety disorders, eating disorders, substance abuse) and to pathological behaviors and personality traits related to anxiety, impulsivity and stress (Serretti et al., 2006). Concerning antidepressant pharmacogenetics, increasing evidence suggest that in Caucasian l allele is associated with better response, although negative findings have been reported as well (Table 1). On the other hand, in Asians an association between s allele and better response was initially reported, though several following studies reported no associations while only few studies found an association with l allele or l/l genotype (see Table 1 and our previous meta-analysis (Serretti et al., 2007b)). So far other ethnicities have not been investigated enough to reach any conclusion. These contradictory findings between Caucasian and other populations may be due to several reasons. Firstly, l allele is much less frequent in Asian compared to Western populations. Indeed: 1. the l/l genotype is present in 29–43% of Caucasians, but in 1–13% of East Asians (Goldman et al., 2010); 2. the s allele is present in 42% of Caucasians, but in 79% of Asians (Kunugi et al., 1997); 3. the s/s genotype varied from 21.6 to 28.3% in the studies including mainly Caucasian patients, while in studies on Asian patients these frequencies varied between 55.6 and 60.0% (Smits et al., 2004). Thus, the low frequency of l allele and l/l genotype in Asians weakens the association between them and response found by some authors. Secondly, other genetic variants within the SERT gene or other related gene may represent further stratification factors. Indeed, a second polymorphism identified within the l allele (rs25531A/G) may determinate a reduced expression of the gene (lG allele), comparable with the expression due to the s allele (Hu et al., 2006). In the light of this finding all the studies performed before the detection of this mutation should be carefully re-examined and future investigations should provide a better covering of the gene (Dong et al., 2009). Finally some recent findings suggested possible interactions between 5-HTTLPR genotype and drug plasma concentration (Lotrich et al., 2008), augmentation strategies (Benedetti et al., 2008, Stamm et al., 2008), life events (Mandelli et al., 2009a) and gender (Walderhaug et al., 2007).
Taken together, these data underline the need for further investigations in order to reach any definitive conclusion. Our previous meta-analysis exploring the association between 5-HTTLPR and antidepressant response, reported positive correlations between l allele and l/l genotype and both response and remission (Serretti et al., 2007b). Despite these results, the increasing amount of data about the topic, especially after the publication of STAR*D results, may be useful to further clarify the role of this relevant polymorphism. These considerations leaded to a new meta-analysis on 5-HTTLPR and antidepressant response. Conversely to our findings, authors did not find any association between 5-HTTLPR and both antidepressant response and remission (Taylor et al., 2010). Nevertheless, they did not perform separate meta-analyses on the basis of the ethnicity that, as stated above, is a well-known confounding factor in pharmacogenetic studies. The confounding role of ethnicity seems even more relevant for 5-HTTLPR, since the very different frequencies of its alleles among different populations (see above) and the increasing evidence of a different effect of 5-HTTLPR in Caucasian and Asian populations (Table 1). As a matter of fact, also Taylor and colleagues observed that ethnicity may be a stratifying factor, thus they included it as moderator in their meta-regression, finding a negative result. Despite this, the limited statistical power of meta-regression approach (Baker et al., 2009) and the previously reported considerations suggest the need of further analysis to clarify this issue. Therefore the aim of the present paper was to perform a meta-analysis on the association between 5-HTTLPR and antidepressant response, firstly considering available studies until November 2010 both on Caucasian and Asian samples to perform an exploratory analysis without any a priori hypothesis. We then tried to dissect the obtained results by separated analysis in Caucasian and Asian populations, in order to reach a relatively definitive conclusion on the role of 5-HTTLPR on the antidepressant response in both the populations in exam. Despite the recent evidence of possible influence exerted by other polymorphisms within SLC6A4promoter, we focus this meta-analysis on the biallelic insertion/deletion polymorphism; indeed, it is the most known and studied so far, while data about the role of the other polymorphisms within the region are still poor and contradictory (Perroud et al., 2010) (see also Discussion). Further, possible modulators of the association were investigated.
Section snippets
Search strategy
An electronic search of the literature was performed to identify association studies investigating the link between 5-HTTLPR and antidepressant response. PubMed, PsycINFO and ISI Web of Knowledge databases were searched for articles published until November 2010 using any combination of the terms “SERT”, “5-HTT”, “SLC6A4”, “serotonin transporter gene”, “HTTLPR” with both “antidepressant”, “SSRIs”, “SSRI”, “SNRIs”, “SNRI”, “NRI”, “Tricyclic”, “response” and “remission”. References from retrieved
Results
An overview of the selected studies on the association between 5-HTTLPR and antidepressant response/remission is provided in Table 1. With regard to studies on the STAR*D sample, we included in the first step of our analysis both the study by Hu et al. (2007) and Mrazek et al. (2009) one at a time, in order to test the impact on the effect size. In the second step, we included the study by Mrazek et al. (2009), since, unlike Hu et al. (2007), it reported results split for ethnic group. On the
Discussion
The aim of this meta-analysis was to elucidate the influence of 5-HTTLPR on antidepressant efficacy, since the studies published so far reached contradictory findings. We retrieved 33 studies to perform an exploratory analysis and test the impact of 5-HTTLPR on antidepressant efficacy without any a priori hypothesis. We found evidence of association between the l/l genotype and l allele and remission (Supplementary Fig. 1). Thus, we tried to dissect the association in order to identify the
Role of the funding source
This study was institutionally supported.
Contributors
Porcelli S. and Fabbri C. performed the electronic search of the literature and carried out a dataset with study information. They equally contributed to the analysis of data and to the drafting of the review. Serretti A. assisted in the preparation of the manuscript and contributed to the drafting of the discussion.
Conflict of interest
Dr. Serretti is or has been a consultant/speaker for: Abbott, Astra Zeneca, Clinical Data, Boheringer, Bristol Myers Squibb, Eli Lilly, GlaxoSmithKline, Janssen, Lundbeck, Pfizer, Sanofi, and Servier.
References (89)
The prognosis of antidepressive treatments: longitudinal and genetic studies
Anglo Ger. Med. Rev.
(1965)- et al.
5-HTTLPR polymorphism of the serotonin transporter gene predicts non-remission in major depression patients treated with citalopram in a 12-weeks follow up study
J. Clin. Psychopharmacol.
(2003) - et al.
Norepinephrine and serotonin transporter genes: impact on treatment response in depression
Neuropsychobiology
(2010) - et al.
Psychosocial and clinical predictors of response to pharmacotherapy for depression
J. Psychiatry Neurosci.
(2002) - et al.
Understanding heterogeneity in meta-analysis: the role of meta-regression
Int. J. Clin. Pract.
(2009) - et al.
Serotonin transporter polymorphism (5-HTTLPR) association with melancholic depression: a female specific effect?
Depress Anxiety
(2008) - et al.
Lithium overcomes the influence of 5-HTTLPR gene polymorphism on antidepressant response to sleep deprivation
J. Clin. Psychopharmacol.
(2008) - et al.
Association study of paroxetine therapeutic response with SERT gene polymorphisms in patients with major depressive disorder
World J. Biol Psychiatry
(2008) - et al.
Interaction between genetic polymorphisms and stressful life events in first episode depression
J. Affect. Disord.
(2009) - et al.
Serotonin transporter gene polymorphisms and sertraline response in major depression patients
Genet. Test.
(2008)
Sequence variations of ABCB1, SLC6A2, SLC6A3, SLC6A4, CREB1, CRHR1 and NTRK2: association with major depression and antidepressant response in Mexican-Americans
Mol. Psychiatry
The serotonin transporter polymorphism, 5HTTLPR, is associated with a faster response time to sertraline in an elderly population with major depressive disorder
Psychopharmacology (Berl)
Meta-analysis: principles and procedures
BMJ
Familial concordance of fluvoxamine response as a tool for differentiating mood disorder pedigrees
J. Psychiatr. Res.
The serotonin transporter polymorphism (5-HTTLPR): allelic variation and links with depressive symptoms
Depress Anxiety
5-HTTLPR modulates antidepressant efficacy in depressed women
Psychiatr. Genet.
Gender issues in depression
Ann. Clin. Psychiatry
Depression: the benefits of early and appropriate treatment
Am. J. Manag. Care
Allelic variation of human serotonin transporter gene expression
J. Neurochem.
Measuring inconsistency in meta-analyses
BMJ
No predictors of antidepressant patient response to milnacipran were obtained using the three-factor structures of the Montgomery and Asberg Depression Rating Scale in Japanese patients with major depressive disorders
Psychiatry Clin. Neurosci.
Response to fluoxetine and serotonin 1A receptor (C-1019G) polymorphism in Taiwan Chinese major depressive disorder
Pharmacogenomics J.
Serotonin transporter promoter gain-of-function genotypes are linked to obsessive–compulsive disorder
Am. J. Hum. Genet.
Association between a functional serotonin transporter promoter polymorphism and citalopram treatment in adult outpatients with major depression
Arch. Gen. Psychiatry
Moderation of antidepressant response by the serotonin transporter gene
Br. J. Psychiatry
Is 5-HTTLPR linked to the response of selective serotonin reuptake inhibitors in MDD?
Eur. Arch. Psychiatry Clin. Neurosci.
Age-dependent antidepressant pharmacogenomics: polymorphisms of the serotonin transporter and G protein beta3 subunit as predictors of response to fluoxetine and nortriptyline
Int. J. Neuropsychopharmacol.
Association study of the serotonin transporter promoter polymorphism and mirtazapine antidepressant response in major depressive disorder
Progress in Neuro-Psychopharmacology and Biological Psychiatry
Review and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder
Mol. Psychiatry
Effects of the serotonin type 2A, 3A and 3B receptor and the serotonin transporter genes on paroxetine and fluvoxamine efficacy and adverse drug reactions in depressed Japanese patients
Neuropsychobiology
Serotonin transporter gene polymorphism and antidepressant response
Neuroreport
Monoamine transporter gene polymorphisms and antidepressant response in Koreans with late-life depression
Jama
Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response
Mol. Psychiatry
A 40-basepair VNTR polymorphism in the dopamine transporter (DAT1) gene and the rapid response to antidepressant treatment
Pharmacogenomics J.
Sequence analysis of the serotonin transporter and associations with antidepressant response
Biol. Psychiatry
Analysis of association between the serotonin transporter and antidepressant response in a large clinical sample
Biol. Psychiatry
Serotonin transporter gene polymorphisms: ethnic difference and possible association with bipolar affective disorder
Mol. Psychiatry
Serotonin transporter promoter gene polymorphism and long-term outcome of antidepressant treatment
Psychiatr. Genet.
Serotonin transporter gene polymorphism associated with short-term treatment response to venlafaxine
Neuropsychobiology
Serotonin transporter genotype interacts with paroxetine plasma levels to influence depression treatment response in geriatric patients
J. Psychiatry Neurosci.
Remission, dropouts, and adverse drug reaction rates in major depressive disorder: a meta-analysis of head-to-head trials
Curr. Med. Res. Opin.
Contribution of allelic variations to the phenotype of response to antidepressants and antipsychotics
Eur. Arch. Psychiatry Clin. Neurosci.
Antidepressant response in the elderly
Psychiatry Res.
Interaction between SERTPR and stressful life events on response to antidepressant treatment
Eur. Neuropsychopharmacol.
Cited by (278)
Pharmacogenetics of selective serotonin reuptake inhibitors (SSRI): A serotonin reuptake transporter (SERT)-based approach
2024, Neurochemistry InternationalOrganic cation transporters in psychiatric and substance use disorders
2024, Pharmacology and TherapeuticsPharmacogenomics in allogeneic hematopoietic stem cell transplantation: Implications on supportive therapies and conditioning regimens
2023, Best Practice and Research: Clinical HaematologyPharmacogenomics testing: An overview
2023, Pharmacogenomics: from Discovery to Clinical ImplementationPharmacogenomics in drug discovery and development
2023, Pharmacogenomics: from Discovery to Clinical ImplementationRegion-specific microRNA alterations in marmosets carrying SLC6A4 polymorphisms are associated with anxiety-like behavior: Marmoset SLC6A4 polymorphisms, anxiety and region-specific miRNAs
2022, eBioMedicineCitation Excerpt :Serotonin neurotransmission is particularly prominent in the regions of the ventro-medial prefrontal cortex (vmPFC) that are dysregulated in patients.15,16 Finally, these polymorphisms have also been associated with poor treatment response to ADs.17,18 In support of human findings, several groups have found an association between SLC6A4 polymorphisms in other primates and phenotypes relevant to psychiatric symptoms.19–22
- 1
Authors contributed equally to the manuscript.